Arkis BioSciences nets FDA nod for neuro catheter

The CerebroFlo is FDA-cleared for the external drainage of cerebrospinal fluid in patients with high brain pressure, intraventricular hemorrhage and hydrocephalic shunt infections. (Arkis BioSciences)

The FDA has cleared Arkis BioSciences’ external ventricular drainage catheter, which relieves high brain pressure and other conditions by draining cerebrospinal fluid.

The CerebroFlo catheter is inserted into the ventricular cavity of the brain for the external drainage of fluid in patients with high brain pressure, intraventricular hemorrhage—bleeding into the brain’s ventricular cavity—and hydrocephalic shunt infections.

The company will debut the device at the Congress of Neurological Surgeons in October, with plans to launch it internationally in 2018, according to a statement.

Sponsored By Syneos Health

Blazing a Trail to Clinical Trial Diversity: Four-Part Webinar Series from Syneos Health, Featuring Pharma, Clinical Research and Community Health Leaders

This series will identify obstacles that stifle appropriate patient diversity in trials; unpack the organizational overhaul needed; share how sponsors, patients & investigators have come together to overcome hurdles; and explore how policy innovations can move the industry forward.

"Arkis' CerebroFlo catheter is the first neuro catheter to incorporate Endexo, a permanent polymer additive whose properties have been shown to reduce protein adhesion and activation in laboratory in vitro studies," CEO Chad Seaver said in a statement. "The catheter's Endexo formulation has properties that may lead to reduced complications such as catheter occlusion and infection."

Knoxville, Tennessee-based Arkis emerged from stealth last year, raising $3.4 million in its series A round in June. The company focuses on surgical instrumentation and catheter technology to make implantable drug delivery, as well as ventricular drainage procedures, less invasive and more durable.